Monoclonal antibody target engagement is controllable with the presence or absence of small molecule KRasG12C inhibitors

Hap10 technologies offer the promise of treating resistance to covalent inhibitors of oncoproteins

From the UCSF Laboratories of Charles Craik and Kevan Shokat, with Ziyang Zhang and Peter Rohweder

(click pictures for bios and publications)